Benzinga | Nov 1, 2021 07:34AM EDT

Centessa Pharmaceuticals Demonstrates Proof-Of-Mechanism From First Three PiMZ Subjects Dosed In Part B Of Phase 1 Study Evaluating ZF874

~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~~W0:

~ One subject with two-fold higher exposure experienced reversible ALT and AST elevations ~~W0:

~ Several actions underway to accelerate enrollment to refine dose and regimen for Phase 2 study expected to start in 2Q 2022 ~~W0:

~ Conference call and webcast scheduled for today at 8:30 a.m. EDT ~~W0: